The optimization of Randomization and Trial Supply Management (RTSM) is not always straightforward, especially as clinical trial designs become more complex (e.g., adaptive designs). Rapid changes in standard-of-care treatment—can make a clinical trial protocol obsolete before the sponsor implements a study. In addition, global clinical trials face mounting competition for patients in an environment with tightening privacy and security considerations for patients and trial supplies, respectively. Specifically, the recently passed General Data Protection Regulation (GDPR), which regulates personal data in the European Union, not only affects European drug sponsors but is relevant to every multinational company with a European presence.

Furthermore, expectations remain high that clinical development teams will successfully implement and execute clinical programs, despite limited available resources.

Download the white paper to see how we provide an in-depth analysis of the importance of optimizing your RTSM system for your organization by focusing on the following areas:

• Reduce significant financial losses and decrease delays
• Appropriate planning and implementation best practices
• Leveraging experienced partners can increase efficiencies